Y. Chen, C. Hu, und Y. Wang. Biostatistics (Oxford, England), 7 (4):
515-29(Oktober 2006)5077<m:linebreak></m:linebreak>JID: 100897327; 2006/02/14 aheadofprint; ppublish;<m:linebreak></m:linebreak>Risc atribuïble.
Y. Wang, L. Meyerson, Y. Tang, und N. Qian. Journal of the neurological sciences, 285 (1-2):
206-11(Oktober 2009)5489<m:linebreak></m:linebreak>JID: 0375403; 0 (Antibodies, Monoclonal); 0 (Immunologic Factors); 0 (natalizumab); 2009/03/05 received; 2009/07/15 revised; 2009/07/22 accepted; 2009/08/25 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de dades; Count data.
R. Chappell. Clinical cancer research : an official journal of the American Association for Cancer Research, 18 (8):
2127-9(April 2012)6822<m:linebreak></m:linebreak>CI: (c)2012; JID: 9502500; CON: Clin Cancer Res. 2012 Apr 15;18(8):2301-8. PMID: 22282466; 2012/03/16 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència; Competing risks.
P. Silcocks. Journal of epidemiology and community health, 63 (10):
856-61(Oktober 2009)5278<m:linebreak></m:linebreak>JID: 7909766; aheadofprint;<m:linebreak></m:linebreak>Anàlisi de supervivència.
V. Stel, F. Dekker, G. Tripepi, C. Zoccali, und K. Jager. Nephron. Clinical practice, 119 (3):
c255-60(Januar 2011)6596<m:linebreak></m:linebreak>CI: Copyright (c) 2011; JID: 101159763; 2011/09/14 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència; Introductori; Nefrologia.
J. Robins, M. Hernán, und A. Rotnitzky. American journal of epidemiology, 166 (9):
994-1002; discussion 1003-4(November 2007)4950<m:linebreak></m:linebreak>GR: R01-HL080644/HL/NHLBI NIH HHS/United States; GR: R37-AI032475/AI/NIAID NIH HHS/United States; JID: 7910653; CON: Am J Epidemiol. 2007 Nov 1;166(9):985-93. PMID: 17875580; 2007/09/17 aheadofprint; ppublish;.